# A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer

> **NCT04329429** · PHASE2 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 57 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** RC48-ADC

## Key facts

- **NCT ID:** NCT04329429
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-24
- **Primary completion:** 2023-11-03
- **Final completion:** 2024-06-30
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04329429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04329429, "A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04329429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*